AbbVie (ABBV)

In a move that signals a decisive shift in the treatment of chronic autoimmune conditions, Gilead Sciences (NASDAQ:GILD) announced on March 23, 2026, its definitive agreement to acquire Ouro Medicines for approximately $2.175 billion. The deal marks Gilead’s second massive investment in the immunology sector within a

In a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF (NYSEARCA: XBI) and the Nasdaq Biotechnology Index (NASDAQ: IBB) struggled to find their footing in late March 2026, dropping

The Schwab U.S. Dividend Equity ETF is increasing its allocation to healthcare dividend stocks.

Eli Lilly is much more than just a weight loss stock.

INDIANAPOLIS – In a move that has left some retail investors scratching their heads, shares of Eli Lilly and Company (NYSE:LLY) have trended lower this week, despite the pharmaceutical giant releasing stellar long-term clinical data for its atopic dermatitis (eczema) treatment, Ebglyss. The disconnect between the laboratory and the trading

The stock has averaged annual gains of 16.2% over the past decade, and it sports a generous dividend yield, too.

Today’s Date: March 26, 2026 Introduction As the global mental health crisis reaches unprecedented levels, the pharmaceutical industry has been forced to look beyond traditional SSRIs toward more radical, rapid-acting interventions. At the forefront of this neuro-psychiatric revolution stands GH Research PLC (Nasdaq: GHRS), a Dublin-based biopharmaceutical firm that has just crossed a critical threshold [...]

Investors should be prepared in case inflation remains higher than expected.

This pair busts the myth of the sector being a desert for income investors.

Shares of pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) climbed 3.3% in early trading on Monday, March 23, 2026, after the company issued a surprisingly robust financial outlook for the fiscal year. Investors rallied behind the company’s projection of significant revenue growth and resilient earnings, signaling a renewed confidence

AbbVie has strong financials, a great dividend, and its stock trades at a modest valuation.

In a landmark decision for the dermatology sector, the U.S. Food and Drug Administration (FDA) has officially approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral peptide for the treatment of moderate-to-severe plaque psoriasis. Developed through a high-stakes collaboration between Protagonist Therapeutics (Nasdaq: PTGX) and Johnson & Johnson (NYSE: JNJ), the approval marks

They have the means to recover from recent setbacks.

These great dividend stocks are especially attractive in the current market conditions.

The pharmaceutical giant AbbVie (NYSE: ABBV) experienced a sharp decline on Wednesday, March 18, 2026, as its stock price tumbled to its lowest level since mid-2025. Shares of the Illinois-based company fell nearly 4% during the session, trading in the range of $211 to $219, a stark contrast to the

Shares of AbbVie Inc. (NASDAQ: ABBV) are moving lower Wednesday. The stock appears to be trending down after a competitor announced significant progress made on a treatment for plaque psoriasis.

Only the best dividend stocks can achieve "king" status.

There are lots of choices, but these are at the top of my list.

Howard Hughes owns large land holdings in fast-growing markets such as Las Vegas, Houston, and Phoenix, where it has developed master-planned communities over many years. Investors will watch whether the company can convert housing demand into both land sales and long-term retail, office, and mixed-use development.

They are relatively safe wealth compounders.

These companies are highly unlikely to go under, no matter what happens.